Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126680) titled 'Evaluating the Impact of Neoadjuvant Chemotherapy Combined with Trastuzumab ± Pertuzumab/Pyrrolopyrimidine on the Success Rate of Breast-Conserving Surgery in Breast Cancer Patients' on June 13.
Study Type: Observational study
Study Design:
Factorial
Primary Sponsor: Guangxi Medical University Cancer Hospital
Condition:
breast cancer
Intervention:
Dual-target group (exposure group): neoadjuvant therapy with chemotherapy plus Trastuzumab and Pertuzumab or Pyrotinib:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-06-30
Target Sample Size: Dual-target group (expo...